[Intra-arterial infusion chemotherapy in the treatment of advanced breast cancer--doxorubicin versus epirubicin].
Doxorubicin (ADM) and epirubicin (epi-ADM) were tested at a dose of 150mg given intraarterially to 31 patients (ADM 14, epi-ADM 17) with advanced breast cancer. The clinical response rate was 78.6% in ADM (1 CR and 10 PR) and 76.5% in epi-ADM (1 CR and 12 PR). The histological response rate of 57.1% was also obtained in ADM and 56.3% in epi-ADM. No significant differences were evident between the two drugs. As for side effects, hair loss and gastrointestinal disorders were frequently documented low grade and less following administration of epi-ADM as compared to ADM. A more favorable prognosis seems possible with epi-ADM compared with ADM. Intra-arterial infusion chemotherapy with epi-ADM appears to be effective for the treatment of advanced breast cancer and is less toxic that ADM.